Beneficial effects of Gelsemium-based treatment against paclitaxel-induced painful symptoms
- 54 Downloads
Chemotherapeutic drugs induce various side effects including painful peripheral neuropathy that represents a major concern. The widely used anticancer drug paclitaxel causes neurological side effects such as burning pain, allodynia, and hyperalgesia. Neuroprotective substances that may effectively counteract paclitaxel-induced neuropathic symptoms are needed. Here, we investigated the potential of Gelsemium sempervirens (GS) to counteract paclitaxel-evoked painful neuropathy in rats. Using the von Frey hair and acetone behavioral tests, we investigated the potential of GS centesimal (C) dilutions 3, 5, and 9C to prevent or to correct paclitaxel-induced cold allodynia and mechanical allodynia/hyperalgesia involved in neuropathic pain. We found that a prophylactic or corrective treatment with GS dilutions prevented or suppressed PAC-evoked cold allodynia and mechanical allodynia/hyperalgesia, by reversing to normal, decreased cold thermal and mechanical pain thresholds of PAC-treated rats. In particular, preventive or corrective treatments with GS dilution 3C counteracted PAC-evoked allodynic and hyperalgesic responses. Also, GS dilution 5C (in a lesser extent than 3C) significantly reduced PAC-induced mechanical allodynia/hyperalgesia while GS dilution 9C was ineffective. PAC-evoked neuropathic symptoms were efficiently reduced after 1 week treatment with GS dilutions 3 or 5C and the beneficial action increased after 2 weeks. GS dilutions, particularly 3C, also counteracted or prevented PAC-induced sciatic nerve axon alterations and decreased the density of intraepidermal nerve fibers. Altogether, these results obtained in the rat preclinical model suggest that GS dilution-based treatment may constitute an interesting option to explore for the long-term management of pain without undesirable effects.
KeywordsChemotherapy-induced painful neuropathy Allodynia Hyperalgesia Therapeutic strategy Gelsemium
This work was supported by grants from the University of Strasbourg and INSERM.
The study was granted by the University of Strasbourg and INSERM.
Compliance with ethical standards
Conflict of interest
BOIRON financially supported the project, provided the treatments, but did not take legal responsibility for the study, which was sponsored by the University of Strasbourg and INSERM. NB from BOIRON contributed to the study design but did not participate in the realization of the study or in data analysis and interpretation.
Animal care and manipulations were performed according to The European Community Council Directives (2010/63/UE) and under the supervision of authorized investigators. All experiments performed minimized the number of animals used and their suffering in accordance with the Alsace Department of Veterinary Public Health Guide for the Care and Use of Laboratory Animals. A national project authorization was delivered by the French Ministry of Higher Education and Research and by CREMEAS a local ethical committee (Project authorization number 9373). The experiments also followed the International Association for the Study of Pain ethical guidelines.
- 21.Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15Google Scholar
- 22.van den Bent MJ, van Raaij-van den Aarssen VJ, Verweij J, Doorn PA, and Sillevis Smitt PA (1997) Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 20:750–752Google Scholar
- 24.Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061CrossRefGoogle Scholar
- 33.Pathirathna S, Brimelow BC, Jagodic MM, Krishnan K, Jiang X, Zorumski CF, Mennerick S, Covey DF, Todorovic SM, Jevtovic-Todorovic V (2005) New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5alpha-reduced neuroactive steroids. Pain 114:429–443CrossRefGoogle Scholar
- 37.Venard C, Boujedaini N, Mensah-Nyagan AG, Patte-Mensah C (2011) Comparative analysis of gelsemine and Gelsemium sempervirens activity on neurosteroid allopregnanolone formation in the spinal cord and limbic system. Evid Based Complement Alternat Med 2011:407617Google Scholar
- 39.Bremner JD (1999) Alterations in brain structure and function associated with post-traumatic stress disorder. Semin Clin Neuropsychiatry 4:249–255Google Scholar
- 41.Haines DE, Mihailoff GA, Yezierski RP (1997) The spinal cord. In: Haines DE (ed) Fundamental neuroscience. Churchill Livingstone Inc., New York, pp 129–141Google Scholar
- 50.Jouany J, Poitevin B, Saint-Jean Y, Masson JL (2003) Gelsemium sempervirens. In: Boiron (ed) Pharmacologie et Matière Médicale Homéopathique. CEDH, Paris, pp 337–383Google Scholar
- 55.Shaw G, Osborn M, Weber K (1986) Reactivity of a panel of neurofilament antibodies on phosphorylated and dephosphorylated neurofilaments. Eur J Cell Biol 42:1–9Google Scholar
- 59.Thompson JM, Neugebauer V (2017) Amygdala plasticity and pain. Pain Res Manag 2017:8296501Google Scholar
- 68.Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R (2008) Opioid complications and side effects. Pain Physician 11:S105–S120Google Scholar